A federal appeals court stay has revived in-person rules for abortion pills nationwide while Louisiana presses its case that mail-order access is unlawful and harmful.
Story Snapshot
- Fifth Circuit stay revives in-person dispensing as Louisiana challenges 2023 mail-order rules.
- State cites Medicaid costs and alleged injuries to claim standing and harm.
- Complaint seeks to vacate Food and Drug Administration changes and block mail shipments.
- Twenty-one attorneys general and 60 lawmakers filed briefs backing Louisiana.
What Triggered the Court Fight
Louisiana sued the Food and Drug Administration in 2025 to overturn the agency’s 2023 policy that allowed the abortion drug mifepristone to be prescribed by telehealth and sent by mail. The 72-page complaint asks a federal court to declare the 2023 changes unlawful, restore earlier in-person rules, and issue injunctions stopping mail dispensing. The case names Louisiana and an individual plaintiff, Rosalie Markezich, and argues the state must shoulder costs and enforcement burdens that follow wider, remote access to the drug.
The Food and Drug Administration changed the Risk Evaluation and Mitigation Strategy for mifepristone in 2023. That move expanded access beyond the older, in-person model. Louisiana’s attorney general says those “pre-Biden era rules” protected patient safety and state law, and that returning to in-person dispensing is “good common sense”. The suit argues that mail delivery and telehealth prescribing undermine Louisiana’s abortion restrictions and make it harder to verify patient age, gestational limits, and consent.
Why the Fifth Circuit Stepped In
The United States Court of Appeals for the Fifth Circuit issued a stay in July 2026 that effectively reinstated nationwide in-person dispensing while the case proceeds. The court summarized Louisiana’s filings, noting the state described “numerous illegal abortions in Louisiana” and state Medicaid spending tied to women treated after complications. The stay does not end the case. It preserves older rules during the appeal, which limits mail-order access as courts review the Food and Drug Administration’s 2023 decision.
Louisiana’s standing claim rests on state costs and alleged harms. A filing by drug maker Danco in the Supreme Court stay fight describes the Fifth Circuit’s view of standing as tied to about $92,000 in Medicaid bills for two women who needed emergency care in 2025 after complications tied to out-of-state mifepristone. Critics of the suit say that number is small for such broad relief, but the Fifth Circuit still allowed the challenge to move forward while facts are weighed.
The Human Story Louisiana Put Forward
The complaint includes the story of plaintiff Rosalie Markezich. Reports say she alleges a former partner got the drug and pressured her to take it, which the suit frames as an example of how mail access and looser controls can enable coercion and abuse. The attorney general’s team also cited six investigated cases of women allegedly harmed or “poisoned” by abortion medications when arguing for tighter rules in public comments around the case. These accounts support Louisiana’s push to restore in-person safeguards pending final judgment.
Support for Louisiana’s position extends beyond one state. Reports say 21 attorneys general and 60 members of Congress filed briefs backing the lawsuit, which underscores how the fight has become national in scope. This coalition argues the Food and Drug Administration moved too far, too fast, and that states should not bear costs or risks from a federal rule that, in their view, weakens key checks around a serious medical event.
What This Means for Patients, States, and Power
The dispute reaches far past one drug. After the Supreme Court’s Dobbs decision, fights over abortion have shifted into courtrooms that test who sets the rules: federal agencies or the states. Louisiana’s case uses administrative law and state-cost claims to challenge a national health policy. The Fifth Circuit’s stay shows how one appeal can reset the ground for everyone while judges weigh whether the Food and Drug Administration lawfully changed the rules in 2023.
A federal appeals court is weighing Louisiana’s effort to reinstate restrictions on how mifepristone, the abortion pill, can be prescribed and dispensed.
During Wednesday’s hearing, judges questioned whether Louisiana has legal standing to challenge the FDA’s 2023 decision… pic.twitter.com/oKGkalKkQt
— Just the News (@JustTheNews) September 10, 2026
The Food and Drug Administration says it regulates drugs based on safety and evidence. Academic and agency records show the agency has updated mifepristone rules several times over the last decade as it reviewed data and logistics. But states like Louisiana argue that mail-order abortion breaks local law and shifts health and policing burdens onto state systems. That clash between federal oversight and state authority now sits at the center of the case, with practical effects on patients, clinics, and insurers.
Sources:
lifesitenews.com, ca5.uscourts.gov, supremecourt.gov, litigationtracker.law.georgetown.edu, ag.state.la.us, guttmacher.org, wwno.org, liveaction.org
